Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.

× No keyword cloud information.

12 in total

1. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal: Ann Rheum Dis Date: 2006-10-26 Impact factor: 19.103

2. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

Authors: Toshihiko Ando; Kensuke Kojima; Hiroshi Isoda; Yuichiro Eguchi; Takashi Honda; Masatoshi Ishigami; Shinya Kimura
Journal: Int J Hematol Date: 2015-04-05 Impact factor: 2.490

3. A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma.

Authors: Toru Takahashi; Tadashi Koike; Shigeo Hashimoto; Tomofumi Miura; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Kazuhide Yamazaki; Shogo Okoshi; Yutaka Aoyagi
Journal: Hepatol Int Date: 2008-09-23 Impact factor: 6.047

4. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.

Authors: Daisuke Shimizu; Kenichi Nomura; Yosuke Matsumoto; Kyoji Ueda; Kanji Yamaguchi; Masahito Minami; Yoshito Itoh; Shigeo Horiike; Masuji Morita; Masafumi Taniwaki; Takeshi Okanoue
Journal: World J Gastroenterol Date: 2004-08-01 Impact factor: 5.742

Review 5. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors: Masaru Kato; Tatsuya Atsumi
Journal: Rheumatol Int Date: 2015-11-16 Impact factor: 2.631

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.

1. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

2. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

3. A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma.

4. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.

Review 5. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

6. Innovative strategies in lymphoma therapy.

Review 7. Hepatitis B virus reactivation with a rituximab-containing regimen.

Review 8. Hepatitis B virus reactivation with rituximab-containing regimen.

9. Rituximab administration and reactivation of HBV.

10. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.